Oncofetal antigens as emerging targets in chimeric antigen receptor (CAR)-T cell-based immunotherapies: opportunities and challenges
Oncofetal antigens are emerging targets for chimeric antigen receptor (CAR)-based immunotherapies due to their developmentally restricted expression and frequent re-emergence in malignant cells. These antigens are tightly linked to cellular plasticity, stem-like programs, immune evasion, and resistance to cytotoxic the...